News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

SRT plus GnRH agonist with acetate/prednisone, apalutamide improves prostate cancer survival
24 Feb 2023
byStephen Padilla
Postoperative salvage radiotherapy (SRT) plus 6 months of androgen deprivation therapy (ADT) with abiraterone acetate/prednisone (AAP) and apalutamide (Apa) results in better progression-free (PFS) and metastasis-free survival (MFS) among patients with prostate cancer, findings from FORMULA-509 have shown. However, the primary analysis did not reach the prespecified threshold for statistical significance.
24 Feb 2023







